Introduction
============

Rupture of intracranial aneurysm (IA) is a contributing factor for hemorrhagic stroke which is characterized by high fatality and disability rates.[@b1-ndt-15-779] A systematic review and meta-analysis found that the prevalence of unruptured IA is about 3.2%.[@b2-ndt-15-779]

The genetic risk factors associated with IA and the strength of their associations with IA remain uncertain.[@b3-ndt-15-779] Thus, the underlying genetics of IA should be further explored. Moreover, IA-related genetic polymorphisms in diverse populations are not entirely the same. Many initial studies have been carried out in populations of European descent, and it is still a challenge to extend the studies to other populations, especially to populations of Asian and African descent.[@b4-ndt-15-779] Compared with other populations, genetic studies on IAs have rarely been carried out in Chinese populations, which is ill-matched with the increasing rate of sequencing in China.[@b5-ndt-15-779] Two genetic variations in the *Sox17* gene, rs1072737 (NC_000008.11: g.54501764T\>G) and rs9298506 (NC_000008.10:g.55437524A\>G), have been shown to be risk factors for IA.[@b6-ndt-15-779]--[@b8-ndt-15-779] However, there have not been any studies to test these findings in the Chinese people. Genotype-phenotype associations in different populations are essential to establish credibility; thus, it is important to study IA-related single nucleotide polymorphisms (SNPs) in *Sox17* in the Chinese population. To further establish the credibility of the relationship between IA and the *Sox17* risk allele in diverse populations, we studied the IA-related single nucleotide variants of *Sox17*, and discoveries of *Sox17* SNPs associated with IA were made in Chinese Han people.

Patients and methods
====================

Ethics approval and informed consent
------------------------------------

All the studies complied with the Declaration of Helsinki and were approved by the Institutional Review Board and Ethics Committee of Tianjin Medical University General Hospital and the collaborating hospitals' ethics committees. All the participants reported themselves to be of Han nationality and provided written informed consent.

Patients and blood samples
--------------------------

This case-control study included 595 patients with sporadic IAs and 600 controls. We recruited patients with IAs between February 2014 and March 2017 from three clinical centers located in Tianjin (Tianjin Medical University General Hospital), Shandong (Linyi People's Hospital), and Hunan (Xiangya Hospital). All IA cases were confirmed to have IA by imaging or surgery. The IA diagnosis was based on symptoms suggestive of subarachnoid hemorrhage (SAH), subarachnoid blood on computed tomography (CT), computerized tomography angiography (CTA), digital subtraction angiography (DSA), and/or surgery. All cases with confirmed IAs based on angiography were retrospectively confirmed by three independent observers, a neuroradiologist, and two highly qualified cerebrovascular neurosurgeons who were blinded to the clinical history and the imaging results. All the patients included in this research underwent either endovascular embolization or a neurosurgical operation after confirmation of the IA. All patients were asked whether they had a family history of IA. The patients with no family history of IA were included.

A total of 600 controls were randomly selected from the Physical Examination Center in the Tianjin Medical University General Hospital (TJMUGH). For an extended period, the Physical Examination Center collected the clinical information and the blood of healthy patients and built a database that provided information on the sex, age, blood pressure, smoking status, alcohol usage and other IA-related indexes for this study. In 2016, TJMUGH united 28 high-level hospitals from different regions in China and established the Chinese Multicenter Cerebral Aneurysm Database (CMAD). The CMAD is a cloud database that consists of clinical information and blood samples (<http://www.cmadtj.com/>). The CMAD contributed data for IA cases in this study.

Selection of SNPs
-----------------

The *Sox17* variants were selected based on the frequency of these variants in the Chinese population and based on the previous genome-wide association study (GWAS) on the *Sox17* gene. The rate of *Sox17* variants in the Chinese population was determined using the NCBI (National Center for Biotechnology Information) database (<http://www.ncbi.nlm.nih.gov/SNP/>).

Genotyping of SNPs
------------------

Genomic DNA was extracted from peripheral blood. All of the obtained DNA samples were stored at −80°C. All the primers were designed by MassArray Assay Design 3.1 (Sequenom Inc., San Diego, CA, USA). SNPs were geno-typed via the Sequenom MassArray system (BioMiao Biotechnology (Beijing) Co. Ltd) and analyzed with the MassArray Typer 4.0 software (Sequenom).[@b9-ndt-15-779]

Statistical analysis
--------------------

First, we checked the grouping information using the ID of the blood sample and the SNP data. Second, the data were tested and analyzed in PLINK (version 1.9).[@b10-ndt-15-779] Finally, when the outcomes were determined, the data were tabulated for further discussion. Multiple-testing was performed in PLINK to make the statistics more rigorous and accurate.

Results
=======

Case and control characteristics and statistical outcome
--------------------------------------------------------

Characteristics of the cases and controls are shown in [Table 1](#t1-ndt-15-779){ref-type="table"}. The genotype distribution of the *Sox17* variants rs1072737 and rs9298506 in the cases and controls are shown in [Table 2](#t2-ndt-15-779){ref-type="table"}. rs1072737 and rs9298506 conform to Hardy--Weinberg equilibrium ([Table 3](#t3-ndt-15-779){ref-type="table"}).

The allele G of rs1072737 is a risk factor for IA, while the allele G of rs9298506 is a protective factor for IA. Multiple-testing correction was performed to verify the risk effect of rs1072737 and the protective effect of rs9298506 with. Both rs1072737 and rs9298506 passed the multiple-testing method "genomic control" (GC) ([Table 4](#t4-ndt-15-779){ref-type="table"}).[@b11-ndt-15-779] The results were clear and definite in the chi-squared test (rs1072737: OR 1.306, genomic-control corrected *P*-value =0.001599; rs9298506: OR 0.7121, genomic-control corrected *P*-value =0.02359) and in the allelic gene logistic regression (rs1072737: OR: 1.303, genomic-control corrected *P*-value =0.01559; rs9298506: OR: 0.7253, genomic-control corrected *P*-value =0.001032) ([Table 4](#t4-ndt-15-779){ref-type="table"}). Additionally, rs9298506 passed other multiple-test methods such as the Bonferroni adjusted method and the Benjamini and Hochberg adjusted method ([Table 4](#t4-ndt-15-779){ref-type="table"}).[@b12-ndt-15-779],[@b13-ndt-15-779]

Discussion
==========

In our study, we found that allele G of rs1072737 is a risk factor for IA, while allele G of rs9298506 is a protective factor for IA. This finding is based on the multiple-testing correction.

A previous GWAS showed that rs1072737 and rs9298506 the *Sox17* were associated with IA.[@b6-ndt-15-779]--[@b8-ndt-15-779] However, the present study indicates that they have different roles in IA in Chinese Han population: the allelic C of rs1072737 is a risk allele, while the allelic G is a protective allele in Chinese Han people ([Table 4](#t4-ndt-15-779){ref-type="table"}). The GWAS showed rs9298506 (*P*=1.3×10^−12^, OR: 1.28, posterior probability of association \>0.9999) to be significantly associated with IA.[@b6-ndt-15-779],[@b8-ndt-15-779] Additionally, rs9298506 was reported to have an IA-related risk effect in another meta-analysis.[@b3-ndt-15-779] Nonetheless, in our study, allele G of rs9298506 was a protective factor for IA in Chinese Han people. Recently, the relationship between *Sox17* gene polymorphisms and IA was investigated in a homogeneous Korean population.[@b15-ndt-15-779] It was shown that allele G of rs1072737 is a protective factor (OR: 0.69, 95%CI: 0.49--0.96, *P*=0.03) and that allele G of rs9298506 has no statistical significance. The results of this study in the Korean population are contrary to our results and others.

Some initial findings cannot be replicated in the follow-up studies due to some issues.[@b14-ndt-15-779],[@b15-ndt-15-779] For risk alleles and the hap-lotypes, initial studies and follow-up studies may not be the same in different populations.[@b16-ndt-15-779]--[@b20-ndt-15-779] Therefore, the confidence would be higher if we evaluated the genotype-phenotype association in people of diverse ancestries, regardless of whether the genotype-phenotype association is derived from candidate-gene studies or genome-wide association studies.[@b4-ndt-15-779] Concordant findings in similar studies are necessary to confirm the genotype-phenotype associations.[@b4-ndt-15-779]

*Sox17* is primarily expressed in the arterial endothelial cells in the early stages of embryonic development. This expression pattern and distribution continues into adulthood.[@b21-ndt-15-779] It suggests that the change in *Sox17* expression leads to abnormalities in intracranial artery differentiation.[@b21-ndt-15-779] A study demonstrated that IA could be generated through induced hypertension and circle of Willis damage by elastase in Sox17-knockdown mice, which further supports the theory that hereditary and acquired risk factors facilitate IA formation.[@b22-ndt-15-779] It was shown that *Sox17* has specific expression in the cerebral artery. Furthermore, compared with that in the normal cerebral artery, the *Sox17* expression in IA is reduced and the endothelial junctions are destablized.[@b22-ndt-15-779] Therefore, we assume that gene *Sox17* variations lead to the function changes of Sox17, cause damage to cerebral artery, and finally promote IA formation. However, molecular biology experiments and a reliable animal model are required to explore the specific mechanisms further.

Conclusion
==========

The allelic G of rs1072737 is a risk factor for IA while the allelic G of rs9298506 serves as a protective factor for IA in Chinese Han people.
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###### 

The distribution of sporadic IA and control cases

                          Sporadic IA   Control cases   *P*-value
  ----------------------- ------------- --------------- -----------
  N                       595           600             
  Women, n (%)            342 (57.5)    219 (36.5)      \<0.001
  Age, years                                            
   Mean ± SD              60.93±11.93   43.50±11.04     
   Range                  17--91        25--94          
  Risk factors                                          
   Hypertension, n (%)    342 (57.5)    122 (20.3)      \<0.001
   Hyperglycemia, n (%)   51 (8.6)      46 (7.7)        \<0.001
   Smoke, n (%)           170 (28.6)    191 (31.8)      \<0.001
   Drink, n (%)           82 (13.8)     191 (31.8)      \<0.001

**Abbreviation:** IA, intracranial aneurysm.

###### 

Genotype statistics

  SNP         Mutant type   Wild type   IA group   Control group                    
  ----------- ------------- ----------- ---------- --------------- ----- ---- ----- -----
  rs1072737   G             T           21         180             372   16   152   424
  rs9298506   G             A           30         164             363   44   217   323

**Note:** A1 and A2 are allelic genes, A1 is the mutant type, A2 is wild type.

**Abbreviations:** SNP, single nucleotide polymorphism; IA, intracranial aneurysm.

###### 

Hardy--Weinberg equilibrium

  SNP         Test                                               A1   A2   Genotype (A1A1/A1A2/A2A2)   O(HET)   E(HET)   *P*-value
  ----------- -------------------------------------------------- ---- ---- --------------------------- -------- -------- -----------
  rs1072737   ALL[a](#tfn4-ndt-15-779){ref-type="table-fn"}      G    T    37/332/796                  0.285    0.2878   0.7598
  rs1072737   AFF[b](#tfn4a-ndt-15-779){ref-type="table-fn"}     G    T    21/180/372                  0.3141   0.3124   1
  rs1072737   UNAFF[c](#tfn4b-ndt-15-779){ref-type="table-fn"}   G    T    16/152/424                  0.2568   0.2625   0.6376
  rs9298506   ALL                                                G    T    74/381/686                  0.3339   0.3562   0.03755
  rs9298506   AFF                                                G    T    30/164/363                  0.2944   0.3213   0.04868
  rs9298506   UNAFF                                              G    T    44/217/323                  0.3716   0.3859   0.3907

**Notes:**

All cases;

Case group;

Control group.

**Abbreviations:** O(HET), observed heterozygosity; E(HET), expected heterozygosity; SNP, single nucleotide polymorphisms.

###### 

Chi-squared test and logistic regression (add model) with multiple-testing correction

  SNP                                   UNADJ      OR       GC         BONF      HOLM     SIDAK_SS   SIDAK_SD   FDR_BH    FDR_BY
  ------------------------------------- ---------- -------- ---------- --------- -------- ---------- ---------- --------- ---------
  **Chi-squared test**                                                                                                    
  rs9298506                             0.000679   0.7121   0.001599   0.01696   0.017    0.01683    0.01683    0.01696   0.06473
  rs1072737                             0.0148     1.306    0.02359    0.3699    0.3403   0.3111     0.2903     0.1233    0.4705
  **Logistic regression (add model)**                                                                                     
  rs9298506                             0.001032   0.7253   0.001032   0.03097   0.031    0.03051    0.03051    0.03097   0.1237
  rs1072737                             0.01559    1.303    0.01559    0.4676    0.4364   0.3758     0.3559     0.1559    0.6227

**Abbreviations:** UNADJ, unadjusted *P*-value; GC, genomic-control corrected *P*-values; BONF, Bonferroni single-step adjusted *P*-values; HOLM, Holm (1979) step-down adjusted *P*-values; SIDAK SS, Sidak single-step adjusted *P*-values; SIDAK SD, Sidak step-down adjusted *P*-values; FDR_BH, Benjamini and Hochberg[@b23-ndt-15-779] step-up FDR control; FDR_BY, Benjamini and Yekutieli[@b24-ndt-15-779] step-up FDR control.
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